Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Drugs Made In America Acquisition II Corp. Ordinary Shares stock (DMII) is currently trading at $9.97. WallStSmart rates DMII as Sell.
- DMII PE ratio analysis and historical PE chart
- DMII PS ratio (Price-to-Sales) history and trend
- DMII intrinsic value — DCF, Graham Number, EPV models
- DMII stock price prediction 2025 2026 2027 2028 2029 2030
- DMII fair value vs current price
- DMII insider transactions and insider buying
- Is DMII undervalued or overvalued?
- Drugs Made In America Acquisition II Corp. Ordinary Shares financial analysis — revenue, earnings, cash flow
- DMII Piotroski F-Score and Altman Z-Score
- DMII analyst price target and Smart Rating
Drugs Made In America Acquisition II Corp.
📊 No data available
Try selecting a different time range
Smart Analysis
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) · 2 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Significant fundamental concerns warrant caution or avoidance.
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) Key Strengths (1)
54.38% held by institutions, strong professional interest
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) Areas to Watch (1)
Small-cap company with higher risk but more growth potential
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) Detailed Analysis Report
Overall Assessment
This company scores 10/100 in our Smart Analysis, earning a F grade. Out of 2 metrics analyzed, 1 register as strengths (avg 8.0/10) while 1 fall into concern territory (avg 5.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Market Cap.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Market Cap improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DMII Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
Insider Transactions
Loading insider activity...
About Drugs Made In America Acquisition II Corp. Ordinary Shares(DMII)
NASDAQ
FINANCIAL SERVICES
SHELL COMPANIES
USA
Drugs Made In America Acquisition II Corp. (DMII) is a special purpose acquisition company (SPAC) focused on merging with innovative firms within the pharmaceuticals and biotechnology sectors to enhance domestic drug manufacturing capabilities. Leveraging the extensive expertise of its management team, DMII identifies and executes strategic transactions that align with rising market demands and prioritize sustainable practices. Through its commitment to fostering resilient supply chains and advancing U.S. healthcare self-sufficiency, DMII aims to deliver sustained value for its shareholders and contribute to the long-term growth of the American pharmaceutical landscape.